SERPLULIMAB BECOMES THE FIRST ANTI-PD-1 APPROVED FOR EXTENSIVE-STAGE SMALL CELL LUNG CANCER .///. SERPLULIMAB APORTA 4,9 MESES MÁS DE OVERALL SURVIVAL QUE ATEZOLIZUMAB EN SOLITARIO ... Y 2,2 MESES MÁS DE OVERALL SURVIVAL QUE ATEZOLIZUMAB COMBINADO CON LURBINECTEDIN .

 

Hawaii Lung 2025 // Corey Langer MD Discusses lMForte Trial And Role Of LURBINECTEDIN In Maintenance SMALL CELL LUNG CANCER , "" HOWEVER TOXICITY IS NOT TRIVIAL "" , Questioning This SOC , CONCERN FOR TOXICITY , Lack Of Crossover And How To Sequence TARLATAMAB .

 

AQUI EL CURRÍCULUM Y LA OPINIÓN DEL DOCTOR COREY LANGER ... SOBRE LOS RESULTADOS  PRESENTADOS DEL IMFORTE EN EL CONGRESO SOBRE PULMÓN EN HAWAI .

Corey J. Langer is a Professor of Medicine at the University of Pennsylvania, Perelman School of Medicine, where he serves as Clinical Director of Thoracic Oncology in the Abramson Cancer Center .

Professor Langer received his medical degree from Boston University in 1981 and completed his residency in medicine at the Graduate Hospital, University of Pennsylvania, and his hematology/oncology fellowship at Presbyterian University of Pennsylvania and Fox Chase Cancer Center in 1987 .

Professor Langer served in the Oncology division of Fox Chase Cancer Center from 1986–2008, leading its Thoracic Oncology Program from 1994–2008 . He moved to the University of Pennsylvania in 2008, where he currently leads clinical research efforts in thoracic malignancy as part of the Interdisciplinary Thoracic Oncology Program (I-TOP) and conducts research studies focused on the role of targeted therapy and immunotherapy in NSCLC .

He also co-directs the Thoracic Translational Center of Excellence, where he concentrates on the clinical end of bench to bedside projects .

Professor Langer is Co-Chair of the Medical Oncology Committee for NRG Cooperative Oncology Group and serves on the core thoracic committees of both NRG and ECOG . 

Professor Langer is a Fellow of the American College of Physicians and is a member of the American Society of Clinical Oncology (ASCO), the American Association for Cancer Research (AACR) and the International Association for the Study of Lung Cancer (IASLC) .

Since 2016, he has been Editor-in-Chief of the International Lung Cancer News (ILCN) UNDERWENT the aegis of the IASLC . 

For the past 34 years, since completing his fellowship, Professor Langer has led or co-led over 140 clinical trials in both SMALL CELL LUNG CANCER ( SCLC ) and NON-SMALL CELL LUNG CANCER ( NSCLC), as well as MESOTHELIOMA and HEAD and NECK CÁNCER .

 Professor Langer has contributed numerous articles and abstracts to the medical literature and is the author or co-author of over 270 peer-reviewed peer-revie papers .

IAG Y EL SECTOR AÉREO Y AUTOMOVILÍSTICO DE ENHORABUENA ... EL PETROLEO CAE EN EL PRIMER SEMESTRE UN 9% ... Y SIGUE CAYENDO . Y AHORA VIENE LO MEJOR === Bombazo Geológico : Hallan un Yacimiento del ‘ Petróleo del Futuro ’ Valorado en 100.000 MILLONES de € en Francia .

¡¡¡ CAMBIO DE PARADIGMA ENERGÉTICO !!! .

ESTAMOS ANTE EL PETRÓLEO DEL FUTURO ...

MÁS ECOLÓGICO .

MAS ECONOMICO .

Y A SOLO 1200 METROS DE PROFUNDIDAD .

Se trata de una forma específica de hidrógeno que podría ofrecer ventajas tanto económicas como medioambientales . 

Este tipo de recurso, radicado en algunas zonas del planeta, plantea la posibilidad de un cambio de paradigma energético .

Un reciente hallazgo en Europa central, muy cerca de España, ha vuelto a ponerlo en el foco de los análisis y proyecciones de futuro . ...

SERPLULIMAB APPROVED In UK , INDIA & EMA . 1st-Line EXTENSIVE-STAGE SMALL CELL LUNG CANCER . First Anti–PD-1 mAb APPROVED Globally For SCLC . Reached Over 110,000 PATIENTS; APPROVED in ~40 COUNTRIES . COMERCIALIZATIÓN In EUROPE And INDIA Led By INTAS & ACCORD .

 

A VER QUE PACIENTE Y QUE ONCÓLOGO CONTINÚA CON ATEZOLIZUMAB O DURVALUMAB ...

 SABIENDO QUE YA TIENE A SU DISPOSICIÓN SERPLULIMAB ( HETRONIFLY )  Y TISLELIZUMAB  ( TEVIMBRA ) QUE SON MUCHO MAS EFECTIVAS ...

 APORTAN MÁS OVERALL SURVIVAL ASÍ COMO PFS Y ADEMÁS UNOS EFECTOS ADVERSOS TRASITORIOS  Y MANEJABLES .

SE ACABÓ AQUELLO DE TENER QUE ELEGIR COMO TRATAMIENTO DE PRIMERA LÍNEA SMALL CELL LUNG CANCER ... AL ATEZOLIZUMAB ( ROCHE  ) O AL DURVALUMAB ( ASTRAZÉNECA ) .

*.- LOS TRATAMIENTOS DE PRIMERA LÍNEA SMALL CELL LUNG CANCER HAN AUMENTADO UN 100 % ... PACIENTES Y ONCOLOG@S  AHORA PUEDEN ELEGIR ENTRE ATEZOLIZUMAB , DURVALUMAB , SERPLULIMAB O TISLELIZUMAB .

**.- TANTO ROCHE COMO ASTRAZENECA VERÁN REDUCIDOS SUS TRATAMIENTOS Y INGRESOS .